Technology, Healthcare, Industrials Dec 13, 2021 07:39 AM (GMT+8) · EqualOcean
Financial Associated Press, December 13 (Xinhua) recently, the second severe heart disease conference hosted by Shenzhen Hospital of Fuwai Hospital of Chinese Academy of Medical Sciences was held. At the meeting, a good news to save the lives of patients with heart failure came: Suzhou Tongxin medical's innovative product "implantable left ventricular assist system ch-vad" (artificial heart) has been approved for listing, which is the first fully maglev artificial heart officially listed in China. Hu Shengshou, academician of the Chinese Academy of engineering, director of the national cardiovascular disease center and President of Fuwai Hospital, said: the surgical treatment of heart failure in China has entered the era of artificial heart.
Related companies: